Every 8-K that Corcept Therapeutics Inc. (CORT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CORT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CORT filings page.
Corcept Therapeutics Incorporated (CORT) announced that Sean Maduck, President of its Endocrinology division, will retire effective October 1, 2026, and that Justin Gunn will succeed him and fully assume the role that day. Gunn will join the Executive Team and report to Chief Executive Officer Joseph K. Belanoff.
Maduck will provide consulting services to the CEO and executive management under an agreement effective October 1, 2026, with an initial term through September 30, 2027, unless terminated earlier. His cash fee is $57,000 per month, and his previously awarded, outstanding stock options will continue vesting on their original schedules during the consulting term. Either party may terminate with 30 days’ prior written notice. The company stated his resignation was not due to disagreement over its operations, financial statements, policies or practices.
Corcept Therapeutics reported strong second-quarter 2026 results, with product revenue of $256.1 million, a 32 percent increase over the same period in 2025. Korlym and its authorized generic contributed $208.6 million and newly launched Lifyorli generated $47.6 million in its first quarter of sales. Net income was $43.0 million, or $0.36 per diluted share, up from $35.1 million, or $0.29 per share, a year earlier.
Operating expenses rose to $214.8 million, driven mainly by higher selling, general and administrative spending to support Lifyorli’s launch and expansion of the Cushing’s syndrome business. Cash and investments were $544.6 million at June 30, 2026.
Management increased 2026 revenue guidance to $1.1–$1.2 billion and highlighted rapid uptake of Lifyorli in platinum-resistant ovarian cancer after its March 2026 FDA approval. The company also emphasized its late-stage pipeline, including a resubmitted NDA for relacorilant in Cushing’s syndrome with a December 17, 2026 PDUFA date, an expected EMA decision on relacorilant in ovarian cancer this year, a Phase 2b MASH study reading out by year-end, and plans for a Phase 3 ALS trial of dazucorilant.
Corcept Therapeutics has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome. The resubmission includes additional analyses of data from prior studies, as requested by the FDA, and is expected to receive a six-month review.
The filing highlights positive results from Corcept’s GRACE and Phase III GRADIENT trials, a long-term extension study and earlier-stage data, which the company believes show meaningful, durable improvements in Cushing’s symptoms without some serious side effects seen with existing therapies. Relacorilant already holds orphan drug designations and is approved as Lifyorli for platinum-resistant ovarian cancer.
Corcept Therapeutics Incorporated reported results of its 2026 annual stockholder meeting and an update to its equity compensation plan. Stockholders approved an amendment to the 2024 Incentive Award Plan, increasing the shares available under the plan by 8,000,000 shares, with the amended plan effective upon approval on May 21, 2026.
All eight director nominees were elected, and stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and the amended incentive plan, with 53,163,364 votes for, 23,867,363 against, and 263,730 abstentions on the plan proposal.
Corcept Therapeutics reported mixed first-quarter 2026 results, combining strong strategic progress with a temporary loss. Revenue rose to $164.9 million from $157.2 million a year earlier, but higher spending on the Lifyorli launch and Cushing’s growth initiatives pushed operating expenses to $214.5 million, resulting in a net loss of $31.8 million, or $0.30 per diluted share, versus net income of $20.5 million in 2025.
The company ended March 31, 2026 with $515.4 million in cash and investments and increased its 2026 revenue guidance to $950–$1,050 million. The FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer in March, and the regimen was added as a preferred option in NCCN Guidelines in April. Corcept also highlighted promising ALS survival data for dazucorilant and expects numerous trial readouts across oncology, Cushing’s syndrome and MASH, while guiding for a return to profitability in the second quarter of 2026.
Corcept Therapeutics reported that the U.S. Food and Drug Administration has approved its drug Lifyorli (relacorilant), used with nab-paclitaxel, to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior bevacizumab-containing regimens.
The approval is based on the pivotal ROSELLA trial in 381 patients, where Lifyorli plus nab-paclitaxel cut the risk of death by 35 percent (hazard ratio 0.65; p=0.0004) and improved median overall survival to 16.0 months, versus 11.9 months with nab-paclitaxel alone. It also reduced the risk of disease progression by 30 percent (hazard ratio 0.70; p=0.008).
Lifyorli is described as the first FDA-approved selective glucocorticoid receptor antagonist and showed a manageable safety profile, though prescribing information carries warnings for neutropenia, severe infections, adrenal insufficiency, exacerbation of glucocorticoid-treated conditions and embryo-fetal toxicity, with common side effects including low blood counts, fatigue, nausea, diarrhea, rash and decreased appetite.
Corcept Therapeutics reported solid 2025 growth while earnings declined as it increased spending on development and commercialization. Revenue rose to $761.4 million from $675.0 million, and fourth-quarter revenue grew to $202.1 million from $181.9 million.
Full-year net income fell to $99.7 million from $141.2 million as selling, general and administrative expenses climbed to $448.7 million. The company ended 2025 with $532.4 million in cash and investments and spent $245.9 million on share repurchases and equity-related payments. It issued 2026 revenue guidance of $900–$1,000 million and highlighted an extensive pipeline, including NDAs for relacorilant in Cushing’s syndrome and platinum-resistant ovarian cancer, Phase 2b MASH data expected by the end of 2026, and plans for a Phase 3 ALS trial of dazucorilant.
Corcept Therapeutics reported that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two Corcept patents covering methods of safely co‑administering Korlym with CYP3A4‑inhibiting drugs commonly used by patients with Cushing’s syndrome.
The decision affirms a prior December 2023 verdict from the Federal District Court for the District of New Jersey. Corcept’s CEO said the company is disappointed with the ruling and plans to vigorously defend its intellectual property, including evaluating options to seek further judicial review of the decision.
Corcept Therapeutics announced that ROSELLA, its pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. This means the treatment combination achieved its main goal of improving how long patients live in this hard-to-treat setting. The company shared this outcome through a press release attached as an exhibit, signaling a key late-stage milestone for relacorilant in oncology.
Corcept Therapeutics (CORT) furnished an 8-K stating it issued a press release with financial results for the quarter ended September 30, 2025 and a corporate update. The release, dated November 4, 2025, is attached as Exhibit 99.1.
The information under Items 2.02 and 7.01 is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless expressly stated.
Corcept Therapeutics (CORT) terminated its distribution services agreement with Optime Care, delivering notice on October 10, 2025, with termination effective January 8, 2026. Optime had served as a specialty pharmacy distributor for Korlym and Corcept’s authorized generic mifepristone, handling pharmacy operations, patient access, reimbursement support, claims, A/R, and reporting.
The agreement, originally dated August 4, 2017 and amended and restated April 1, 2024, had been extended through March 31, 2027 with automatic three-year renewals. Corcept previously informed Optime that, under its contractual rights, Optime’s exclusivity ended on September 15, 2025. The contract permitted termination for convenience by Corcept with 90-days advance notice, as well as customary remedies for material breach.
Corcept Therapeutics Incorporated reported that board member Gillian Cannon, Ph.D. has resigned from its Board of Directors, effective October 10, 2025. The company states that Dr. Cannon did not resign because of any disagreement regarding its operations, financial statements, policies or practices, indicating this is a non-controversial transition.
Corcept has entered into a Consulting Services Agreement with Dr. Cannon, effective as of her resignation date, under which she will provide consulting services to the Board until the company’s 2026 stockholder meeting. As compensation, she will receive a cash fee of $5,708.33 per month, and her previously granted, outstanding stock options will continue to vest on their original schedules during the consulting term.
Corcept Therapeutics filed a report stating that the U.S. Food and Drug Administration has accepted its New Drug Application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. This acceptance means the FDA has agreed to review the application for this potential new therapy.